Neurocrine Biosciences Q4 EPS of $1.69 beat estimates, while revenue missed consensus. Ingrezza sales rose 23% to $615 million. 2025 Ingrezza sales guidance fell short of Street estimate.

INGREZZA Sales Guidance for 2025: $2.5 billion to $2.6 billion, reflecting $250 million growth at the midpoint. CRENESSITY Q4 2024 Sales: $2 million in net sales from initial bottle orders.

He emphasized the strong performance of INGREZZA, which is poised for double-digit year-over-year growth despite moderated expectations compared to 2024, the company’s highest growth year to date.

On Thursday, Neurocrine Biosciences Inc. (NASDAQ:NBIX) reported fourth-quarter adjusted EPS of $1.69, higher than the $1.54 reported a year ago, beating the consensus of $1.56. The company ...

February 3, 2025, FRANKFORT, IL ― The Home Fire Sprinkler Coalition (HFSC) will select 40 fire departments to each receive a $750 stipend to conduct a Home Fire Sprinkler Week outreach program ...

FY25 revenue consensus $2.79B. Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions. Monitor your stock ...

Among the stars turning 40 in 2025 are Oscar-nominated actresses Keira Knightley and Amanda Seyfried, singers Bruno Mars and Janelle Monáe, not to mention former child stars including Frankie ...

FD&C Red No. 40, more commonly known as red 40, is making headlines again as lawmakers debate whether food dyes should remain legal in the United States. The dye, which has been registered with ...

Although MG hasn’t revealed exact specifications yet, going by the dimensions of the international-spec D90 Max, the Majestor could measure 5,046mm in length, 2,016mm in width and 1,876mm in ...